Specialties

Targeted Oncology | Dialogues in Diagnostics
Targeted Oncology | Differential Diagnosis
Targeted Oncology | Case-Base Peer-Perspective

Top Medical News Today

Combination of Encorafenib and Binimetinib Improves PFS in Melanoma
Part 1 of the phase III COLUMBUS trial has shown positive results for the combination of the BRAF inhibitor encorafenib (LGX818) and the MEK inhibitor binimetinib (MEK162) for patients with BRAF-mutant melanoma.
Metformin Shows Positive Results in Endometrial Cancer
Findings from a recent phase II trial1 showed that combining the diabetes drug metformin with everolimus (Afinitor) and letrozole resulted in a clinical benefit rate (CBR) of 60% in women with advanced or recurrent endometrioid endometrial cancer.
Ceritinib Improves Progression-Free Survival in ALK+ NSCLC
According to results from the phase III ASCEND-4 trial, ceritinib (Zykadia) improved progression-free survival (PFS) compared with standard chemotherapy as a first-line treatment for patients with ALK-positive non–small cell lung cancer (NSCLC)
Hope Rugo, MD, clinical professor, department of medicine, and director of Breast Oncology Clinical Trials Program, at University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the role of immunotherapy in breast cancer.
Patricia LoRusso, DO, PhD, professor of medicine and associate director of Innovative Medicine at Yale Cancer Center, discusses the key questions that still remain regarding combination and sequencing with PARP inhibitors.
PARP Inhibitors Still Alive, But Not Alone, in Triple-Negative Breast Cancer
PARP inhibitors are anything but dead as breast cancer treatment, argued Patricia LoRusso, DO. 
View More >

Features

Mesa Provides Tips for Treating Myelofibrosis After Ruxolitinib
Mesa Provides Tips for Treating Myelofibrosis After Ruxolitinib
Developing a treatment plan for myelofibrosis patients who fail ruxolitinib requires an understanding of both current treatment options and those that are expected to become available within the next several years.
Immunotherapy May Be Next Frontier for AML, Says Daver
Immunotherapy offers promise in acute myeloid leukemia (AML), a disease type which has not seen significant progress in many years, said Naval G. Daver, MD
Blinatumomab Receives FDA Approval for Acute Lymphoblastic Leukemia
Blinatumomab (Blincyto) has received accelerated approval from the FDA for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
NDA for Neratinib in HER2-Positive Breast Cancer Accepted by FDA
A new drug application (NDA) for neratinib as an extended adjuvant therapy for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab (Herceptin) has been accepted by the FDA
FDA Gives Niraparib Fast Track Designation for Ovarian Cancer
Niraparib has been granted a fast track designation by the FDA as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
Publications